Prelude Therapeutics (PRLD) Net Cash Flow (2019 - 2026)
Prelude Therapeutics (PRLD) posted Net Cash Flow of -$13.5 million for Q1 2026, down 9.97% sequentially from -$12.3 million in Q4 2025, and down 148.57% YoY from $27.8 million in Q1 2025.
Prelude Therapeutics (PRLD) Net Cash Flow (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Net Cash Flow for 8 years, with the latest figure at -$13.5 million in Q1 2026.
- Quarterly Net Cash Flow fell 148.57% year-over-year to -$13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.3 million (down 224.16% YoY) and the FY2025 annual result came in at $22.0 million, up 271.44% from the prior year.
- Net Cash Flow fell to -$13.5 million in Q1 2026 per PRLD's latest filing, from -$12.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $27.8 million in Q1 2025 and troughed at -$21.4 million in Q4 2022.
- A 5-year average of -$640058.8 and a median of -$584000.0 in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 4859.42% in 2025, down 1016.12% in 2025.
- Over 5 years, Net Cash Flow stood at -$21.4 million in 2022, then soared by 143.87% to $9.4 million in 2023, then sank by 85.74% to $1.3 million in 2024, then tumbled by 1016.12% to -$12.3 million in 2025, then fell by 9.97% to -$13.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$13.5 million, -$12.3 million, and $21.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.74 Mn |
| Jun 30, 2026 | 4.74 Mn |
| Mar 31, 2026 | -13.50 Mn |
| Mar 31, 2026 | -13.50 Mn |
| Dec 31, 2025 | -12.28 Mn |
| Dec 31, 2025 | -12.28 Mn |
| Sep 30, 2025 | 20.97 Mn |
| Sep 30, 2025 | 20.97 Mn |
| Jun 30, 2025 | -14.52 Mn |
| Jun 30, 2025 | -14.52 Mn |
| Mar 31, 2025 | 27.80 Mn |
| Mar 31, 2025 | 27.80 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | -16.69 Mn |
| Sep 30, 2024 | -16.69 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | -584,000.00 |
| Mar 31, 2024 | -584,000.00 |